BOOKS BY CATEGORY
Your Account
Design of Hybrid Molecules for Drug Development
Price
Quantity
€176.90
(To see other currencies, click on price)
Paperback / softback
Add to basket  

MORE ABOUT THIS BOOK

Main description:

Design of Hybrid Molecules for Drug Development reviews the principles, advantages, and limitations involved with designing these groundbreaking compounds. Beginning with an introduction to hybrid molecule design and background as to their need, the book goes on to explore a range of important hybrids, with hybrids containing natural products, molecules containing NO- and H2S-donors, dual-acting compounds acting as receptor ligands and enzyme inhibitors, and the design of photoresponsive drugs all discussed.

Drawing on practical case studies, the hybridization of molecules for development as treatments for a number of key diseases is then outlined, including the design of hybrids for Alzheimer's, cancer, and malaria.

With its cutting-edge reviews of breaking developments in this exciting field, the book offers a novel approach for all those working in the design, development, and administration of drugs for a range of debilitating disorders.


Contents:

1. Introduction
2. Multitarget-Directed Antioxidants as Therapeutic Agents: Putting the Focus on the Oxidative Stress
3. Towards Gaseous Mediator Hybrid Drugs
4. Designed Hybrid Compounds for Tropical Parasitic Diseases
5. Dual-Acting Compounds Acting as Receptor Ligands and Enzyme Inhibitors
6. Multitarget Anti-Alzheimer Hybrid Compounds: Do They Work In Vivo?
7. Anticancer Hybrids
8. Molecular Hybridization: An Emerging Tool for the Design of Novel Therapeutics for Alzheimer's Disease
9. Computational Methods in Multitarget Drug Discovery
10. Medicinal Chemistry of Hybrids for Neurodegenerative Diseases
11. Photoresponsive Hybrid Compounds


PRODUCT DETAILS

ISBN-13: 9780081010112
Publisher: Elsevier (Elsevier / The Lancet)
Publication date: April, 2017
Pages: 360
Weight: 740g
Availability: Available
Subcategories: Pharmacology

CUSTOMER REVIEWS

Average Rating